- Home
- CLSD vs RANI Comparison
CLSD vs RANI Comparison
Compare CLSD & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- RANI
- Stock Information
- Founded
- CLSD 2011
- RANI 2012
- Country
- CLSD United States
- RANI United States
- Employees
- CLSD N/A
- RANI N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- CLSD Health Care
- RANI Health Care
- Exchange
- CLSD Nasdaq
- RANI Nasdaq
- Market Cap
- CLSD 20.4M
- RANI 24.2M
- IPO Year
- CLSD 2016
- RANI 2021
- Fundamental
- Price
- CLSD $2.75
- RANI $1.68
- Analyst Decision
- CLSD Hold
- RANI Strong Buy
- Analyst Count
- CLSD 4
- RANI 6
- Target Price
- CLSD $75.00
- RANI $8.67
- AVG Volume (30 Days)
- CLSD 42.9K
- RANI 11.1M
- Earning Date
- CLSD 11-14-2025
- RANI 11-06-2025
- Dividend Yield
- CLSD N/A
- RANI N/A
- EPS Growth
- CLSD N/A
- RANI N/A
- EPS
- CLSD N/A
- RANI N/A
- Revenue
- CLSD $3,329,000.00
- RANI $1,200,000.00
- Revenue This Year
- CLSD $98.20
- RANI N/A
- Revenue Next Year
- CLSD $213.77
- RANI N/A
- P/E Ratio
- CLSD N/A
- RANI N/A
- Revenue Growth
- CLSD N/A
- RANI N/A
- 52 Week Low
- CLSD $2.54
- RANI $0.39
- 52 Week High
- CLSD $17.10
- RANI $3.87
- Technical
- Relative Strength Index (RSI)
- CLSD 33.87
- RANI 49.08
- Support Level
- CLSD $2.54
- RANI $1.79
- Resistance Level
- CLSD $4.00
- RANI $1.99
- Average True Range (ATR)
- CLSD 0.34
- RANI 0.28
- MACD
- CLSD -0.16
- RANI -0.10
- Stochastic Oscillator
- CLSD 10.47
- RANI 19.23
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.